Hamadani, Mehdi. 2022. “Did Brentuximab vedotin’s Rise to the Top ECHELON of Hodgkin Therapeutics Invalidate AETHERA Results?”. Haematologica 107 (7). Pavia, Italy, 1500-1502. https://doi.org/10.3324/haematol.2021.280284.